top of page

News and Updates

April: Tour of New Zealand Riders Raise over $18k for NECNZ!

Cyclists of Team Unicorn have successfully completed the demanding Tour of New Zealand, showcasing not only their endurance and teamwork but also their dedication to a meaningful cause. Through their incredible efforts, the team raised over $18,000 for Neuroendocrine Cancer community of  NZ.T This generous contribution will help NECNZ continue its vital work—supporting patients, raising awareness, and funding research into neuroendocrine cancers.

 

The Tour of NZ was once again, more than a cycling challenge; it was a powerful journey of purpose and heart, making a real difference for New Zealanders living with neuroendocrine cancer.

Click here for more information and photo gallery

Mobile PET Banner.png

March 2025 - ​Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging 

 

Access to advanced diagnostic imaging has taken a significant leap forward with the introduction of Gallium-68 Dotatate PET-CT scans now available through Mobile Imaging's mobile service. Starting March 31st, this service will make a profound difference for individuals in rural and remote areas, providing diagnostic services closer to home. Gallium-68 Dotatate PET-CT scans are a highly effective tool for diagnosing and assessing neuroendocrine tumours, providing precise imaging that supports accurate treatment planning. 

 

Mobile Health Group and Mercy Radiology partnered together in 2024 to roll out Mobile Imaging – NZ’s first state-of-the-art mobile PET-CT unit, designed to travel across regions, ensuring that PET-CT scans are no longer confined to urban centres. 

Since then, it has travelled to Rotorua, Palmerston North, Lower Hutt, and Dunedin.

 

Dr Remy Lim, Medical Director of Mercy Radiology says, “The introduction of Gallium-68 Dotatate scans onboard Mobile Imaging is making this cutting-edge technology even more accessible, particularly in rural and remote areas. Gallium-68 Dotatate PET-CT imaging represents a significant step forward in diagnosing neuroendocrine tumours, a group of rare cancers that can be challenging to detect. This advanced radiotracer is helping doctors pinpoint these tumours with greater accuracy than ever before.” 

 

Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers. These tumours arise from neuroendocrine cells and although commonly found in the digestive or respiratory systems, they can develop anywhere in the body. The term neuroendocrine implies that these cells have received some nervous connections, (neuro- ) and the cells can secrete hormones (endocrine).

 

By bringing advanced diagnostic services directly to local communities, Mobile Imaging is breaking down barriers and ensuring that all New Zealanders have access to cutting-edge healthcare, regardless of where they live.

 

Mark Eager, Mobile Health Group CE says, “Until now, accessing this level of imaging often required long journeys as Dotatate is only available in Auckland and Christchurch, posing logistical and financial challenges for many Kiwis.” 

 

Mark adds, “This service not only saves patients from long and costly journeys but also reduces waiting times for scans and diagnosis. By making this advanced imaging more accessible, Mobile Imaging is enhancing equitable healthcare and ensuring timely intervention for those in need.”

For more information, visit www.mobileimaging.co.nz

Source:  Mobile Imaging - March 2025

January 2025: Honouring a Legacy: Malcolm Legget MNZM and His Transformative Impact on NET Cancer Care

Malcolm Legget 1.jpeg

The 2025 New Year Honours list acknowledges the incredible achievements of our beloved former Trustee, Associate Professor Malcolm Legget.

 

Malcolm has been posthumously appointed to be a Member of the New Zealand Order of Merit.

 

The citation says he is being honoured for his contributions to cardiology and for his work in cancer treatment and research for NETs.

 

It is unusual for a person to receive a posthumous award, though not unheard of. The citation says King Charles and the New Zealand government signed off the awards before Malcolm died in November.

The award points out what all of us in the neuroendocrine NZ community know; that Malcolm did so much for neuroendocrine cancer care in New Zealand.

The honours list reads that he “made a significant contribution to cardiology and cancer treatment and research, ensuring access to world leading treatments is available through New Zealand’s public health system… Following his diagnosis with Neuroendocrine cancer (NET) in 2011, he became a leader in ensuring the best treatments possible for NET are available to all New Zealanders.”

 

When faced with his own diagnosis in 2011, Malcolm could have focused on himself and his own family to make the best life he could for the duration of his cancer. But instead he focused on transforming neuroendocrine cancer (NET) treatment in New Zealand. Malcolm felt so lucky to be able to access treatments overseas to extend his own life, and he was determined that all New Zealanders living with NETs deserved the same chance.

 

His achievements for our community include spearheading efforts to set up state of the art neuroendocrine cancer diagnostics in Auckland and bringing PRRT treatment to New Zealand. He raised more than $2 million for research and brought leading specialist Dr Ben Lawrence home from the USA.

 

Malcolm cared about people with NETs and generously shared his knowledge. He was a deeply talented man who applied every ounce of those talents to improve NET cancer care for all Kiwi patients.

 

And on top of all this he laughed easily, cared deeply and had a fierce and abiding love for his wife Carrie and their children George, Harry and Emelia.

 

The Board and CEO of Neuroendocrine Cancer NZ - past and present – acknowledge that Malcolm’s appointment as a Member of the NZ Order of Merit is particularly bittersweet. We wish our humble hero was still here so we could celebrate with him.

 

CEO Michelle Sullivan says everyone is glad of the recognition but saddened Malcolm is not here to celebrate with us.

 

NOTE: Work is underway to establish a fund to honour Malcolm and provide much needed research into NETs treatments. More details will be released in the next few weeks.

November 2024:  Associate Professor Doctor Malcolm Legget 

TONZ26.jpeg

It is with great sadness that we write to let you know that Malcolm Legget, one of the driving forces in securing better treatment for people with Neuroendocrine cancer in Aotearoa New Zealand, has died.

We at Neuroendocrine Cancer NZ are heartbroken but thankful we have been able to share the past 13 years with Malcolm.

Malcolm was one of New Zealand’s foremost cardiologists and made his name through his work, his research and his tireless voluntary efforts promoting heart health. He was a consultant at Green Lane and Auckland City Hospitals, a consultant and board member of the Heart Group, and an Associate Professor at the University of Auckland.

But in 2011, Malcolm found himself at the centre of his own medical diagnosis. He always remembered the date and time that he went to his GP for upper abdominal pain, fatigue and irritable bowel symptoms. He was diagnosed with a pancreatic neuroendocrine tumour with metastases in his liver. He remembered calling his wife, Carrie, and thinking “how am I going to tell the kids?”

There began the work that would anchor his next thirteen years. He worked to stay alive. He wanted to be part of the life of his family, his three children, friends and this community. He wanted to keep working, experience the joy of life and be with people. He sought out treatments wherever he could. And for us in the neuroendocrine cancer community he began to work for a better outcome for people with NETs. Malcolm was fortunately able to travel to Australia but with NET scans costing $3,000 and treatment more than $50,000 he resolved to fight for access for all New Zealanders.

He recognised the need to advance medical knowledge of NETs in NZ. Malcolm founded the Translational Medicine Trust and was the first Chair helping raise an initial $2 million to start the programme and bring leading NET specialist Dr Ben Lawrence home from the US. With more donations, the Trust established the NETwork! Project for neuroendocrine cancer research. It has now published more than 30 peer-reviewed papers, employed 20 people and is regarded as world-class.

He formed a friendship with Siobhan Conroy who had established Unicorn Foundation NZ in 2012 (today Neuroendocrine Cancer New Zealand). He joined the Board in 2014, acting as Chair during a key phase through to 2019, and then stayed on as a Trustee.

In 2015 they spearheaded efforts to raise funds for a Gallium-68 generator. Alongside family and friends, he rode the length of the country and encouraged donors. The first Gallium NET scan was established at Mercy Radiology and since then, every NET patient needing this scan has been able to receive one. It has also been used to help thousands of prostate cancer patients.

From 2016, Siobhan, Malcolm and NECNZ turned to the problem of getting access to Peptide Receptor Radionuclide Therapy (PRRT). They wrote a full Pharmac funding application - no small task - created a petition and delivered 2000 signed letters from patients to Pharmac on the steps of Parliament. It worked. Pharmac and the Ministry of Health approved the treatment in 2017 but delays in setting up the service led to more hard lobbying that eventually saw the Ministry of Health approve funding for 30 patients a year to travel to Melbourne for PRRT at the Peter MacCallum Cancer Centre.

COVID border closures were the catalyst for Auckland City Hospital to establish a PRRT service for New Zealand. The first patients were treated in September 2020, and the service was officially launched in July 2021. This was the first new national cancer treatment service launched in New Zealand for many years. Malcolm was in the auditorium for the Ministerial launch, and later experienced the treatment first hand.

NETs treatment in New Zealand has been transformed thanks to Malcolm’s boundless energy, determination to get things done and his skills in networking. He and his wife Carrie have a huge network and convinced them to help. He talked people into cycling New Zealand, running marathons or donating to the cause. And they did, out of respect for Malcolm and to help his community.

Malcolm was respected by patients for his wide knowledge and experience of NETs treatments - knowledge that he generously shared with many members of our community. He championed the NECNZ hardship fund, which has seen more than 40 patients receive a helping hand to assist with costs of undergoing treatment. 

 

And on top of all this, he was a kind and generous person. He laughed easily. He was funny. Malcolm loved reading and wrote poetry and short stories. He even has several songs on Spotify, as Malcolm and the Murmurs. https://open.spotify.com/artist/21oDdOibGdjLAHSgM1ghAC

In one song, Clouds Inside my Head, he sang:

“Even in the dark we’re still moving forward

Even in the rain we will carry the sword

Following you where no others tread

To clear those clouds inside my head”

He had the unstinting support of Carrie and his children Harry, George and Emelia. Often the whole family was involved in fundraising, with Harry and Emelia running the Auckland and Queenstown marathons this month to raise funds that Malcolm wanted used for NECNZ’s hardship fund and to expand our network of NET nurses.

Malcolm was always determined to do his best to live and live well. But over the last few weeks his health faltered. On Friday evening, Malcolm passed away peacefully surrounded by his family.

Arohanui Malcolm. Thank you for all you have done and for the legacy you leave behind. You will be missed

Read the NZ Herald obituary here: Associate Professor Dr Malcolm Legget - 'No Ordinary New Zealander'

December 2021 -  Unicorn Foundation NZ Founder and Board Member Steps Down

Unicorn Foundation NZ founder, Siobhan Conroy dedicated countless hours to building the organisation from scratch and it is thanks to her endless advocacy for neuroendocrine cancer patients that we have the diagnosis and treatments available today.

As CEO for six years, she made huge advances for neuroendocrine cancer patients, and as a board member for the past three years she has overseen even more gains - most notably implementation of PRRT as a national service.

After working for and on behalf of our community for so many years, Siobhan has decided that 2022 will see her focus more on her family and her thriving new business.

We thank you Siobhan for all your incredibly tireless work, tenacity and commitment to getting Unicorn Foundation NZ off the ground and Neuroendocrine Cancer NZ to where it is today. 

Some of Siobhan's major highlights are listed below:

Siobhan talking.jpg

2013: Unicorn Foundation launched

As a newly diagnosed NET cancer patient, Siobhan went searching for information and was appalled at the lack of support for neuroendocrine cancer patients in New Zealand.Undaunted by this, she established the Unicorn Foundation NZ to focus on patient support, improved access to treatment, increased awareness of these cancers, and supporting research.

2015: GaTate PET scanning launched at Mercy Radiology

Specialist diagnostic scans identify if a NET cancer patient is a suitable candidate for the life-extending treatment called Peptide Receptor Radionuclide Therapy (known as PRRT). But New Zealand had no GaTate PET scanner, which forced patients to travel to Melbourne at their own cost to check if PRRT could help them.
In April 2015, a team of dedicated cyclists rode the length of the North Island to raise money for a state-of-the-art diagnostic GaTate PET scanner that now lives at Mercy Radiology in Auckland, and is accessed by both public- and privately-funded patients.

2016: Specialist NET nurse appointed to support patients

As a patient herself, Siobhan lived and breathed the fact that NET cancers are so diverse that each patient's symptoms vary enormously. She knew that patients living day-to-day with symptoms needed practical advice on living with NETs. A new era began when Siobhan recruited Avril Hull to Unicorn Foundation as our first specialist NET nurse. She was later followed by Lesley Harrison in Christchurch, to provide a South Island focus.
Other patient support Siobhan implemented included cuppa catch ups for patients at cafes around the country, an annual NET patient education day with incredible expert speakers from New Zealand and Australia, a patient-only facebook page and our trademark patient booklet.

2017: PHARMAC support for PRRT

In 2017, PHARMAC considered Unicorn Foundation NZ's PRRT funding case that included expert medical evidence, detailed patient stories and was supported by letters from our more than 2,000 strong NET cancer community. PHARMAC, Ministry of Health and Auckland District Health Board (ADHB) agreed that publicly funded PRRT should be made available to New Zealanders once the systems and relevant expertise are are in place.

2018: Expanding support, expanding advocacy

In 2018 Siobhan brought Christchurch nurse Lesley Harrison onto the Unicorn Foundation team. That saw cuppa catch ups held more frequently in Christchurch and Dunedin and in new locations like Greymouth and Nelson.  To keep these events free for all patients to attend, Siobhan remained a tireless fundraiser, with events like Craft Beer and Bites, fun runs and more epic cycling adventures.  She also worked tirelessly with the media to keep the spotlight on the plight of neuroendocrine cancer patients, who still needed to pay privately and travel to Australia for PRRT.

And now, we have PRRT as a permanent service for New Zealanders

Concern at the continued delays in setting up PRRT led Unicorn Foundation to advocate for High Cost Treatment Pool access for NET cancer patients to access PRRT in Australia.  In October 2019 the Minister of Health agreed to fund up to 30 patients per year under this scheme.
In 2020 COVID-19 in Melbourne saw the Victorian state borders closed, so New Zealand NET patients could no longer access PRRT in Melbourne. Unicorn Foundation NZ was involved in spearheading a cross-agency roundtable to establish an interim PRRT service in Auckland to meet the needs of urgent patients who were no longer able to receive treatment in Melbourne. The first patients received PRRT at ADHB in September 2020. July 2021 saw the Minister of Health formally launch the new, permanent PRRT service at ADHB, delivering on one of the founding goals of Unicorn Foundation.

October 2021 -  Octreotide brand switch

From 1 September 2021 PHARMAC has switched suppliers for octreotide. Prior to 1 September 2021, Novartis supplied Sandostatin LAR, but over the next six months this will shift to Teva's generic octreotide. By 1 March 2022 Teva will supply a minimum of 95% of the market. We have launched a nationwide nurse survey to collect information about the octreotide brand switch and any issues - big or small - that nurses and patients encounter.


The survey will be open for at least six months so we can track the rollout of the generic octreotide.  Over the next six months, we will be reporting the results to PHARMAC, Medsafe and Te Aho o Te Kahu Cancer Control Agency on a regular basis. Our goal is to work collaboratively with these key government agencies to ensure the best care and best treatments for our neuroendocrine cancer community.

The survey is for nurses, but if you're a patient on octreotide, please help us by talking to your nurse about the survey and asking s/he to complete it every time there's something good or bad to report.

14 July 2021 - PRRT Officially Launched in NZ

 

Minister of Health, Hon Andrew Little officially launched the new, permanent, national PRRT service in Auckland on Wednesday 14 July 2021. Unicorn Foundation NZ has spent more than six years advocating for this treatment. Now, any neuroendocrine cancer patient who needs PRRT will be able to access the treatment through the public health system.

Image: Health Minister, Hon. Andrew Little

JLV9557_20210714-15.jpg

Sign up to receive our e-news & updates

  • Facebook
  • Instagram
  • YouTube

Thanks! You'll be added to our mailing list

Neuroendocrine Cancer New Zealand is a registered charity CC49802

bottom of page